• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    NeueHealth Secures up to $150 Million in New Term Loan Facility with Hercules Capital

    6/24/24 6:45:00 AM ET
    $HTGC
    $NEUE
    Investment Managers
    Finance
    Medical Specialities
    Health Care
    Get the next $HTGC alert in real time by email
    • Significantly strengthens balance sheet, positioning Company for long-term, sustainable growth
    • Underscores the value Company delivers to payors, providers, and consumers across the industry

    NeueHealth, Inc. ("NeueHealth" or the "Company") (NYSE:NEUE), the value-driven healthcare company, today announced that it entered into a secured loan facility for up to $150 million with Hercules Capital, Inc. (NYSE:HTGC) ("Hercules").

    "This financing puts us in a strong position to advance our differentiated care model and take the lead as the industry continues to shift to value-based care," said Mike Mikan, President and CEO of NeueHealth. "We have established longstanding relationships with payors, providers, and consumers across the industry, and we look forward to continuing to build on our success as we make personalized care more accessible and affordable for all."

    The financing, which will be used to support NeueHealth's strategic priorities in 2024 and beyond, further solidifies the Company's capital position, enabling it to focus on delivering value-driven, consumer-centric care to all populations.

    "Hercules is pleased to support NeueHealth. We see significant opportunities in NeueHealth's ability to drive value for payors and providers and deliver high-quality care to consumers across the ACA Marketplace, Medicare, and Medicaid," said Tom Hertzberg, Managing Director at Hercules. "NeueHealth is driving value in healthcare for all, and we are thrilled to be their financial partner," added Mike McMahon, Director at Hercules.

    More information regarding the financing and the key terms will be included in a Form 8-K to be filed by NeueHealth with the Securities and Exchange Commission.

    Moelis & Company LLC acted as exclusive placement agent and capital markets advisor and Simpson Thacher & Bartlett LLP served as legal advisor to the Company.

    About NeueHealth

    NeueHealth is a value-driven healthcare company grounded in the belief that all health consumers are entitled to high-quality, coordinated care. By uniquely aligning the interests of health consumers, providers, and payors, NeueHealth helps to make healthcare accessible and affordable to all populations across the ACA Marketplace, Medicare, and Medicaid. NeueHealth delivers high-quality clinical care to over 460,000 health consumers through owned clinics and unique partnerships with over 3,000 affiliated providers. We also enable independent providers and medical groups to thrive in performance-based arrangements through a suite of technology and services scaled centrally and deployed locally. We believe our value-driven, consumer-centric care model can transform the healthcare experience and maximize value across the healthcare system. For more information, visit: www.neuehealth.com.

    Forward-Looking Statements

    Statements made in this release that are not statements of historical fact, including statements about our beliefs and expectations, are forward-looking statements and should be evaluated as such. Forward-looking statements include information concerning possible or assumed future results of operations, including descriptions of our business plan and strategies. These statements often include words such as "anticipate," "expect," "plan," "believe," "intend," "project," "forecast," "estimates," "projections," "outlook," "ensure," and other similar expressions. These forward-looking statements include any statements regarding our plans, expectations and financial guidance. Such forward-looking statements are subject to various risks, uncertainties and assumptions. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. Factors that might materially affect such forward-looking statements include: our ability to continue as a going concern; our ability to comply with the terms of our credit facility or any credit facility into which we enter in the future; our ability to receive the remaining proceeds from the sale of our Medicare Advantage business in California in a timely manner; our ability to obtain any short or long term debt or equity financing needed to operate our business; our ability to quickly and efficiently complete the wind down of our remaining IFP and MA businesses, including by satisfying liabilities of those businesses when due and payable; potential disruptions to our business due to corporate restructuring and any resulting headcount reduction; our ability to accurately estimate and effectively manage the costs relating to changes in our businesses offerings and models; a delay or inability to withdraw regulated capital from our subsidiaries; a lack of acceptance or slow adoption of our business model; our ability to retain existing consumers and expand consumer enrollment; our and our care partner's abilities to obtain and accurately assess, code, and report risk adjustment factor scores; our ability to contract with care providers and arrange for the provision of quality care; our ability to obtain claims information timely and accurately; the impact of any pandemic or epidemic on our business and results of operations; the risks associated with our reliance on third-party providers to operate our business; the impact of modifications or changes to the U.S. health insurance markets; our ability to manage any growth of our business; our ability to operate, update or implement our technology platform and other information technology systems; our ability to retain key executives; our ability to successfully pursue acquisitions and integrate acquired businesses; the occurrence of severe weather events, catastrophic health events, natural or man-made disasters, and social and political conditions or civil unrest; our ability to prevent and contain data security incidents and the impact of data security incidents on our members, patients, employees and financial results; our ability to comply with requirements to maintain effective internal controls; our ability to adapt to mitigate risks associated with our ACO Reach businesses, including any unanticipated market or regulatory developments; and the other factors set forth under the heading "Risk Factors" in the Company's reports on Form 10-K, Form 10-Q, and Form 8-K (including all amendments to those reports) and our other filings with the SEC. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this release to conform these statements to actual results or changes in our expectations.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240624949891/en/

    Get the next $HTGC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HTGC
    $NEUE

    CompanyDatePrice TargetRatingAnalyst
    Hercules Capital Inc.
    $HTGC
    2/13/2026$17.50Overweight → Neutral
    Piper Sandler
    Hercules Capital Inc.
    $HTGC
    11/4/2025$19.50Neutral → Buy
    Compass Point
    Hercules Capital Inc.
    $HTGC
    12/12/2024$19.50 → $21.50Mkt Perform → Outperform
    Keefe Bruyette
    Hercules Capital Inc.
    $HTGC
    1/16/2024$17.00 → $17.50Buy → Neutral
    Compass Point
    Hercules Capital Inc.
    $HTGC
    11/21/2023$17.00Neutral
    UBS
    Hercules Capital Inc.
    $HTGC
    8/30/2023$17.50Neutral → Buy
    Compass Point
    Hercules Capital Inc.
    $HTGC
    8/4/2023$13.50 → $17.00Underperform → Mkt Perform
    Keefe Bruyette
    Hercules Capital Inc.
    $HTGC
    4/6/2023$16.00Neutral → Overweight
    Piper Sandler
    More analyst ratings

    $HTGC
    $NEUE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Hercules Capital Sets New Record with All-Time High New Debt and Equity Commitments

    Hercules Capital, Inc. (NYSE:HTGC) ("Hercules," "Hercules Capital," or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced it has set a new all-time record of $1.81 billion in new debt and equity commitments for the first quarter of 2026. "Coming off a record-breaking performance for gross new debt and equity commitments and fundings in 2025, our momentum accelerated in Q1 — marked by an all-time high in new debt and equity commitments," said Scott Bluestein, chief executive officer and chief investment o

    4/6/26 6:00:00 AM ET
    $HCXY
    $HTGC
    Investment Managers
    Finance

    enGene Reports First Quarter 2026 Financial Results and Provides Business Update

    LEGEND pivotal cohort update planned for a spring 2026 medical conference 12-month complete response data from LEGEND pivotal cohort expected in 2H 2026 Biologics License Application (BLA) submission for detalimogene planned for 2H 2026 Cash and marketable securities of $312.5 million expected to provide cash runway into 2H 2028 Expanded $125 million debt facility with Hercules Capital provides additional financial flexibility to advance detalimogene development and commercialization for bladder cancer enGene Holdings Inc. (NASDAQ:ENGN, "enGene" or the "Company")), a clinical-stage, non-viral genetic medicines company, today announced its financial results for the first quarter en

    3/9/26 7:00:00 AM ET
    $ENGN
    $HTGC
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Investment Managers
    Finance

    Hercules Capital Receives a BBB (high) Affirmed Investment Grade Corporate and Credit Rating from Morningstar DBRS

    Hercules Capital, Inc. (NYSE:HTGC) ("Hercules," "Hercules Capital," or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that Morningstar DBRS ("DBRS") has affirmed Hercules' investment grade corporate and credit rating of BBB (high). DBRS issued a statement announcing the affirmation of the rating and Stable trend, as well as its underlying analysis. According to DBRS, the affirmed BBB (high) credit ratings reflect the Company's well-developed franchise and strong operating performance including resili

    3/4/26 12:16:00 PM ET
    $HCXY
    $HTGC
    Investment Managers
    Finance

    $HTGC
    $NEUE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Hercules Capital downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded Hercules Capital from Overweight to Neutral and set a new price target of $17.50

    2/13/26 8:28:49 AM ET
    $HTGC
    Investment Managers
    Finance

    Hercules Capital upgraded by Compass Point with a new price target

    Compass Point upgraded Hercules Capital from Neutral to Buy and set a new price target of $19.50

    11/4/25 7:20:09 AM ET
    $HTGC
    Investment Managers
    Finance

    Hercules Capital upgraded by Keefe Bruyette with a new price target

    Keefe Bruyette upgraded Hercules Capital from Mkt Perform to Outperform and set a new price target of $21.50 from $19.50 previously

    12/12/24 8:09:58 AM ET
    $HTGC
    Investment Managers
    Finance

    $HTGC
    $NEUE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Chief Operating Officer Follmann Christian bought $73,400 worth of shares (5,000 units at $14.68), increasing direct ownership by 3% to 150,135 units (SEC Form 4)

    4/A - Hercules Capital, Inc. (0001280784) (Issuer)

    3/5/26 5:19:12 PM ET
    $HTGC
    Investment Managers
    Finance

    Chief Operating Officer Follmann Christian decreased direct ownership by 3% to 150,135 units (SEC Form 4)

    4 - Hercules Capital, Inc. (0001280784) (Issuer)

    3/5/26 3:53:29 PM ET
    $HTGC
    Investment Managers
    Finance

    Director Randhawa Paramjeet K bought $45,079 worth of shares (3,050 units at $14.78), increasing direct ownership by 18% to 19,560 units (SEC Form 4)

    4 - Hercules Capital, Inc. (0001280784) (Issuer)

    3/5/26 2:54:35 PM ET
    $HTGC
    Investment Managers
    Finance

    $HTGC
    $NEUE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Badavas Robert P

    4 - Hercules Capital, Inc. (0001280784) (Issuer)

    3/30/26 7:55:51 PM ET
    $HTGC
    Investment Managers
    Finance

    SEC Form 4 filed by Loo Wade

    4 - Hercules Capital, Inc. (0001280784) (Issuer)

    3/30/26 7:46:18 PM ET
    $HTGC
    Investment Managers
    Finance

    SEC Form 4 filed by Fallon Thomas J

    4 - Hercules Capital, Inc. (0001280784) (Issuer)

    3/30/26 7:45:13 PM ET
    $HTGC
    Investment Managers
    Finance

    $HTGC
    $NEUE
    SEC Filings

    View All

    SEC Form ABS-15G filed by Hercules Capital Inc.

    ABS-15G - Hercules Capital, Inc. (0001280784) (Filer)

    2/27/26 5:04:10 PM ET
    $HTGC
    Investment Managers
    Finance

    Hercules Capital Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

    8-K - Hercules Capital, Inc. (0001280784) (Filer)

    2/12/26 4:30:16 PM ET
    $HTGC
    Investment Managers
    Finance

    SEC Form 10-K filed by Hercules Capital Inc.

    10-K - Hercules Capital, Inc. (0001280784) (Filer)

    2/12/26 4:17:15 PM ET
    $HTGC
    Investment Managers
    Finance

    $HTGC
    $NEUE
    Financials

    Live finance-specific insights

    View All

    Hercules Capital Reports Fourth Quarter and Full-Year 2025 Financial Results

    Record Full-Year 2025 Total New Debt and Equity Commitments of $3.92 Billion, an Increase of 45.7% Year-over-Year Record Full-Year 2025 Total Fundings of $2.28 Billion, an Increase of 25.9% Year-over-Year Record Full-Year 2025 Total Investment Income of $532.5 Million, an Increase of 7.9% Year-over-Year Record Full-Year 2025 Net Investment Income "NII" of $341.7 Million, an Increase of 4.9% Year-over-Year Record Q4 2025 Total Gross Debt and Equity Commitments of $1.06 Billion, an Increase of 70.8% Year-over-Year Q4 2025 NII of $0.48 per Share provides 120% Coverage of the Base Cash Distribution Conservative Balance Sheet Management with Net Leverage of 101.8% and Net Regulatory

    2/12/26 4:05:00 PM ET
    $HCXY
    $HTGC
    Investment Managers
    Finance

    Hercules Capital Announces Date for Release of Fourth Quarter and Full-Year 2025 Financial Results and Conference Call

    Hercules Capital, Inc. (NYSE:HTGC) ("Hercules," "Hercules Capital," or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that it has scheduled its fourth quarter and full-year 2025 financial results conference call for Thursday, February 12, 2026, at 2:00 p.m. PT (5:00 p.m. ET). Hercules will release its financial results after market close that same day. All interested parties are invited to participate via telephone or the live webcast, which will be hosted on a webcast link located on the Investor Re

    1/29/26 6:00:00 AM ET
    $HCXY
    $HTGC
    Investment Managers
    Finance

    Hercules Capital Reports Third Quarter 2025 Financial Results

    Q3 2025 Total New Debt and Equity Commitments of $846.2 Million Record Q3 2025 Total Fundings of $504.6 Million Record Year-to-Date Ending Q3 2025 Total Debt and Equity Commitments of $2.87 Billion Record Year-to-Date Ending Q3 2025 Total Fundings of $1.75 Billion Record Q3 2025 Total Investment Income of $138.1 Million Q3 2025 Net Investment Income "NII" of $88.6 Million Q3 2025 NII of $0.49 per Share provides 122% Coverage of the Base Cash Distribution Conservative Balance Sheet Management with Net GAAP Leverage of 98.2% and Net Regulatory Leverage of 82.3%(1) Inclusive of the Adviser Funds Advised by Hercules Adviser LLC, its Wholly-owned Subsidiary, Hercules had over $1.

    10/30/25 4:05:00 PM ET
    $HCXY
    $HTGC
    Investment Managers
    Finance

    $HTGC
    $NEUE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by NeueHealth Inc. (Amendment)

    SC 13D/A - NeueHealth, Inc. (0001671284) (Subject)

    4/10/24 9:52:09 PM ET
    $NEUE
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Hercules Capital Inc.

    SC 13G - Hercules Capital, Inc. (0001280784) (Subject)

    5/8/23 5:06:26 PM ET
    $HTGC
    Investment Managers
    Finance

    SEC Form SC 13G/A filed by Hercules Capital Inc. (Amendment)

    SC 13G/A - Hercules Capital, Inc. (0001280784) (Filed by)

    10/12/22 9:11:00 AM ET
    $HTGC
    Investment Managers
    Finance

    $HTGC
    $NEUE
    Leadership Updates

    Live Leadership Updates

    View All

    Snappt Acquires Trigo to Enhance Applicant Trust Platform for Multifamily Housing, Secures $50M Growth Financing

    Strategic growth financing accelerates expansion through acquisition and supports product innovation Snappt, the leading platform for applicant trust in multifamily housing, today announced it has acquired Trigo, a company known for its breakthrough technology in verifying rental payment history. Backed by a $50 million committed facility from Hercules Capital, Inc. (NYSE:HTGC), the acquisition expands Snappt's platform and strengthens its ability to help property managers make faster, more confident leasing decisions. Together, these milestones mark a major step toward building the industry's most complete and trusted solution embedded into the application and screening process. "This

    8/5/25 12:00:00 PM ET
    $HTGC
    Investment Managers
    Finance

    Revelation Partners Expands Team with Hire of Andrew Olson, Partner, Chief Financial Officer & Chief Operating Officer

    SAUSALITO, Calif., Nov. 29, 2023 /PRNewswire/ -- Revelation Partners, a healthcare investment firm with over $1.5 billion of capital under management, announced today the addition of Andrew Olson as Partner, Chief Financial Officer and Chief Operating Officer. Mr. Olson has an extensive background in the venture capital and funds management industry. His addition to the team will enhance the firm's technical expertise, support the differentiated investment model, and strengthen the firm's ongoing foundation. As the firm's new Chief Financial Officer and Chief Operating Officer

    11/29/23 1:01:00 PM ET
    $HTGC
    $TPVG
    Investment Managers
    Finance
    Other Consumer Services
    Consumer Discretionary

    Hercules Capital Announces the Appointment of Mr. Nikos Theodosopoulos to Its Board of Directors

    Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that Nikos Theodosopoulos was appointed to serve as an independent member of its board of directors, effective September 21, 2023. Mr. Theodosopoulos is an experienced corporate executive and board director with more than 38 years in senior management roles in both the financial services and technology industries. Mr. Theodosopoulos will serve on the Company's Audit Committee. "Nikos' combined experienc

    9/25/23 6:00:00 AM ET
    $HCXY
    $HTGC
    Investment Managers
    Finance